CBUSNCMHealthcare·Biotechnology#364 in industry

Cibus, Inc.

Reports in 10d· 2026-05-07

-17.5% · 90d

$1.49

-0.01 (-0.67%)

After-Hours $1.49(+0.00)

News

(1)

April 2026

Apr 20, 20261 week agoDEF 14AHealthcare

Cibus (CBUS) shareholders vote on board, pay, and independent auditor

CBUSCibus, Inc.

# 📢 What This Document Is 🗓️ This document is a Proxy Statement (DEF 14A), which is essentially an official invitation and rulebook for an Annual Meeting of Stockholders. 📑 Its entire purpose is to explain what matters will be voted on, who the directors are, and how stockholders can cast their v

Read summaryView on SEC EDGAR

Key Data

Market Cap$113.7M

Open$1.52

Prev Close$1.50

Day Range$1.43 – $1.52

52W Range$1.09 – $4.19

Volume565,778

P/E (TTM)—

EPS$-2.78

Dividend Yield—

Beta1.93

Revenue Growth-12.80%

Price Target$14.67(+884.3%)

Next Earnings2026-05-07(10d)

Analyst Ratings

Strong Buy3 analysts

Buy 2Hold 1Sell 0

About

Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients. it has patented core technology platform, RTDS, a scalable, standardized, end-to-end, semi-automated and high-throughput gene-editing system marketed under the Trait Machine brand name. The company was formerly known as Calyxt, Inc. and changed its name to Cibus, Inc. in June 2023. Cibus, Inc. was incorporated in 2010 and is headquartered in San Diego, California.

Healthcare · Biotechnology

118 employees

www.cibus.com